Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 3/20 | 0.49 |
| ▸ | NOS1 | P29475 | 3/20 | 0.49 |
| ▸ | NOS2 | P35228 | 3/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MLYCD | O95822 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13605108 | 0.87 | TAS1R3 (0.49) | TAS1R3TAS1R1L3MBTL1RAB9ANPC1 | |
| SCHEMBL18803703 | 0.86 | NPC1 (0.49) | RAB9ANPC1MLYCDLMNANPSR1 | |
| SCHEMBL5995873 | 0.85 | ALDH1A1 (0.51) | TAS1R3TAS1R1L3MBTL1RAB9ANPC1 | |
| SCHEMBL12984315 | 0.83 | CA2 (0.61) | L3MBTL1RAB9ANPC1CA2CA1 | |
| SCHEMBL12984316 | 0.83 | CA2 (0.61) | L3MBTL1RAB9ANPC1CA2CA1 | |
| SCHEMBL12983607 | 0.83 | TAS1R3 (0.52) | TAS1R3TAS1R1L3MBTL1RAB9AGAA | |
| SCHEMBL13885653 | 0.83 | LNPEP (0.56) | TAS1R3TAS1R1L3MBTL1RAB9AGAA | |
| SCHEMBL12983609 | 0.83 | TAS1R3 (0.52) | TAS1R3TAS1R1L3MBTL1RAB9AGAA | |
| SCHEMBL14195141 | 0.83 | TAS1R3 (0.49) | TAS1R3TAS1R1L3MBTL1RAB9AGAA | |
| Hydrochloric Acid SCHEMBL5926809 | 0.82 | CYP26A1 (0.46) | NOS3NOS1NOS2TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7056924-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-7001909-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-02-21 | — | — | US | disclosed |
| EP-1583760-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | CV Therapeutics Inc. (US) | 2005-10-12 | — | — | EP | disclosed |
| US-6930111-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2005-08-16 | — | — | US | disclosed |
| EP-1406898-B1 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS INC (US) | 2005-04-06 | — | — | EP | disclosed |
| CN-1533388-A | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | CVҽҩ����˾ | 2004-09-29 | — | — | CN | disclosed |
| US-20040176383-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2004-09-09 | — | — | US | disclosed |
| WO-2004067506-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | CV THERAPEUTICS INC. (US) | 2004-08-12 | — | — | WO | disclosed |
| EP-1406898-A1 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030181352-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2003-09-25 | — | — | US | disclosed |
| US-20030176447-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2003-09-18 | — | — | US | disclosed |
| WO-2003008411-A1 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181352-A1 | Substituted heterocyclic compounds | DLD, LPL, HDLBP | NOS3 1684/4885NOS1 2215/4885NOS2 2079/4885 |
| US-20030176447-A1 | Substituted heterocyclic compounds | DLD, LPL, HDLBP | NOS3 1684/4885NOS1 2215/4885NOS2 2079/4885 |
| US-20040176383-A1 | Substituted heterocyclic compounds | DLD, LPL, HDLBP | NOS3 1684/4885NOS1 2215/4885NOS2 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.